NASDAQ · NKTR
Healthcare · Biotechnology
$37.76
Up+$0.98 (+2.60%)
Updated Nov 4, 2026, 2:39 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NKTR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
NKTR closed at $37.76 after 21 trading sessions, down 5.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $37.28 | $38.46 | $37.28 | $37.76 | 429.54K |
| Nov 2, 2026 | $38.65 | $39.01 | $36.7975 | $36.95 | 823.21K |
| Oct 30, 2026 | $39.00 | $39.30 | $38.00 | $38.87 | 600.97K |
| Oct 29, 2026 | $38.35 | $39.89 | $38.35 | $39.18 | 490.3K |
| Oct 28, 2026 | $37.75 | $38.60 | $37.49 | $38.55 | 405.24K |
| Oct 27, 2026 | $37.52 | $38.40 | $37.045 | $37.97 | 568.31K |
| Oct 26, 2026 | $37.18 | $37.915 | $36.935 | $37.45 | 532.6K |
| Oct 23, 2026 | $37.87 | $38.16 | $36.665 | $37.22 | 469.62K |
| Oct 22, 2026 | $38.01 | $38.795 | $36.995 | $38.65 | 1.02M |
| Oct 21, 2026 | $39.09 | $40.35 | $38.25 | $38.27 | 619.43K |
| Oct 20, 2026 | $36.99 | $39.25 | $36.50 | $39.22 | 1.06M |
| Oct 19, 2026 | $36.00 | $36.79 | $35.635 | $36.64 | 831.54K |
| Oct 16, 2026 | $38.05 | $38.05 | $35.61 | $35.78 | 784.3K |
| Oct 15, 2026 | $37.15 | $38.74 | $36.94 | $37.72 | 684.25K |
| Oct 14, 2026 | $37.50 | $37.75 | $36.56 | $36.89 | 1M |
| Oct 13, 2026 | $39.79 | $39.83 | $37.75 | $37.92 | 2.04M |
| Oct 12, 2026 | $40.93 | $40.975 | $39.26 | $39.84 | 1.05M |
| Oct 9, 2026 | $40.38 | $42.38 | $40.33 | $41.17 | 1.17M |
| Oct 8, 2026 | $39.89 | $41.14 | $39.01 | $40.80 | 1.75M |
| Oct 7, 2026 | $39.22 | $40.35 | $38.445 | $40.26 | 1.51M |
| Oct 6, 2026 | $42.44 | $42.44 | $39.34 | $39.91 | 1.96M |
The latest Smart Investors Daily articles mentioning NKTR.
Company
Market Activity
Research & News
NKTR research
Company profile and research snapshot.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Neutral | — |
| Oct 12, 2026 | Leerink Partners | Outperform | — |
| Oct 9, 2026 | BTIG | Buy | — |
| Oct 9, 2026 | Raymond James | Market Perform | — |
| Oct 2, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 30, 2026
Nektarâs rezpegaldesleukin enters phase 3 in atopic dermatitis, with Q1 2027 data ahead. Discover more here on NKTR and our bullish thesis for the stock.
Yahoo · Oct 29, 2026
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 27, 2026
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Yahoo · Oct 23, 2026
Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NKTR.
